论文部分内容阅读
目的:观察盐酸吉西他滨联合顺铂化疗方案治疗晚期非小细胞肺癌(NSCLC)的临床疗效及主要不良反应。方法:选择本科室38例不能手术的Ⅲ、Ⅳ期非小细胞肺癌患者,用盐酸吉西他滨1000 mg/m2(第1、8天)于60 min内静脉滴注,顺铂25 mg/m2(第1、2、3天)静脉滴注,21 d为1周期,治疗2~4个周期后评价;近期疗效评价为完全缓解(CR)、部分缓解(PR)、稳定(SD)和病情进展(PD),以疾病进展时间(TTP)、中位生存期(MST)和1年生存率为远期疗效评价。结果:CR 0例,PR 17例,SD 12例,PD 9例,总有效率(PR+CR)为44.7%(17/38);TTP为4个月、MST为9个月和1年生存率为47.3%(18/38)。主要不良反应为Ⅱ~Ⅲ度骨髓抑制和恶心呕吐。结论:盐酸吉西他滨联合顺铂方案治疗晚期非小细胞肺癌疗效肯定,耐受性较好。
Objective: To observe the clinical efficacy and major adverse reactions of gemcitabine hydrochloride combined with cisplatin in the treatment of advanced non-small cell lung cancer (NSCLC). Methods: Thirty-eight patients with stage Ⅲ and Ⅳ non-small cell lung cancer who were inoperable were enrolled in this study. Patients were given intravenous infusion of gemcitabine hydrochloride 1000 mg / m 2 (days 1 and 8) within 60 min, cisplatin 25 mg / 1, 2, 3 days) intravenously, 21 days for 1 cycle, after 2 to 4 cycles of treatment evaluation; the recent curative effect evaluation for complete remission (CR), partial remission (PR), stable (SD) and progression PD) to evaluate the long-term efficacy of the disease progression time (TTP), median survival (MST) and 1-year survival rate. Results: There were 0 cases in CR, 17 cases in PR, 12 cases in SD and 9 cases in PD. The total effective rate (PR + CR) was 44.7% (17/38). TTP was 4 months and MST was 9 months and 1 year The rate was 47.3% (18/38). The main adverse reactions were grade Ⅱ ~ Ⅲ myelosuppression and nausea and vomiting. Conclusion: The combination of gemcitabine hydrochloride and cisplatin is effective and effective in the treatment of advanced non-small cell lung cancer.